NASDAQ · CTNM
Healthcare · Biotechnology
$17.19
Up+$1.17 (+7.30%)
Updated Aug 22, 2026, 2:39 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CTNM closed at $17.19 after 21 trading sessions, up 22.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $16.18 | $17.35 | $15.8801 | $17.19 | 353.91K |
| Aug 20, 2026 | $15.80 | $16.29 | $15.68 | $16.02 | 321.3K |
| Aug 19, 2026 | $14.87 | $16.15 | $14.60 | $16.02 | 545.56K |
| Aug 18, 2026 | $14.38 | $14.98 | $14.315 | $14.50 | 531.01K |
| Aug 17, 2026 | $14.15 | $15.15 | $14.15 | $14.53 | 2.1M |
| Aug 14, 2026 | $15.33 | $15.66 | $14.10 | $14.19 | 747.31K |
| Aug 13, 2026 | $15.21 | $16.16 | $14.95 | $15.30 | 401.71K |
| Aug 12, 2026 | $14.90 | $15.235 | $14.61 | $14.98 | 1M |
| Aug 11, 2026 | $14.48 | $15.2901 | $14.20 | $14.82 | 903.22K |
| Aug 10, 2026 | $14.93 | $15.11 | $14.22 | $14.49 | 504.45K |
| Aug 7, 2026 | $15.46 | $15.50 | $14.57 | $15.04 | 528.93K |
| Aug 6, 2026 | $15.29 | $15.795 | $14.96 | $15.35 | 227.5K |
| Aug 5, 2026 | $15.98 | $16.56 | $15.10 | $15.27 | 247.88K |
| Aug 4, 2026 | $15.83 | $16.70 | $15.31 | $15.90 | 430.22K |
| Aug 3, 2026 | $15.22 | $16.37 | $15.19 | $15.93 | 315.03K |
| Jul 31, 2026 | $15.75 | $16.08 | $14.125 | $15.49 | 449.58K |
| Jul 30, 2026 | $14.48 | $15.85 | $14.47 | $15.75 | 337.66K |
| Jul 29, 2026 | $14.15 | $14.74 | $13.90 | $14.38 | 174.5K |
| Jul 28, 2026 | $13.88 | $14.56 | $13.26 | $14.16 | 210.88K |
| Jul 27, 2026 | $14.28 | $14.85 | $13.81 | $13.86 | 114.17K |
| Jul 24, 2026 | $14.45 | $14.45 | $13.78 | $14.06 | 122.84K |
The latest Smart Investors Daily articles mentioning CTNM.
CTNM research
Company profile and research snapshot.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | RBC Capital | Outperform | — |
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 6, 2026 | Baird | Outperform | — |
| Jan 8, 2026 | Morgan Stanley | Equal-Weight | — |
| Nov 24, 2025 | Baird | Outperform | — |
No generated briefing is available yet.
Benzinga · Jul 31, 2026
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.
Yahoo · Jul 30, 2026
SAN DIEGO, July 30, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones.
Benzinga · Jul 30, 2026
Contineum has streamlined its discovery programs to focus on drug candidates for the treatment of inflammatory and fibrotic diseases. These actions have resulted in a limited workforce reduction for the Company’s
Benzinga · Jul 30, 2026
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 35.48 percent increase over losses of $(0.62) per
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTNM.
